DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety of Sodium Heparin (Hipolabor) in Patients

Information source: L.A.L Clinica Pesquisa e Desenvolvimento Ltda.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cardiac Surgery

Intervention: Heparin sodium Hipolabor (Biological); Heparin sodium APP (Biological)

Phase: Phase 3

Status: Completed

Sponsored by: L.A.L Clinica Pesquisa e Desenvolvimento Ltda.

Summary

The objective of this study is to verify, through a randomized, single-blind, multicentre, parallel and comparative study, the effectiveness of heparin sodium of porcine origin in patients undergoing heart surgery at that require the aid of cardiopulmonary bypass, through the control of hemostasis during and after surgery, based on the strengths of markers of coagulation TCA, TTPA, Anti-Xa, heparin bioavailable and loss of excessive blood (bleeding) at the end of the surgery.

Clinical Details

Official title: Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention

Primary outcome: Effectiveness of heparin of porcine origin in patients undergoing cardiovascular surgery

Secondary outcome: Evaluation of the average dose and and safety of porcine heparin.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients who agree with all aspects of the study and sign the FICT;

- Patients of both sexes;

- Patients aged above 18 years;

- Patients with cardiac surgery and requiring movement; AND

- Extracorporeal.

Exclusion Criteria:

- Patients with hematological disorders that compromise the surgical changes (eg

myeloproliferative syndromes, anemia Hb <11. 0 g / dL,

- Platelets < 150,000 mm3);

- Patients with disorders of hemostasis (INR> 1. 40) (rTTPA> 1. 40);

- Patients with renal dysfunction (creatinine> 1. 50);

- Patients with deep hyperthermia;

- Liver disease (AST and ALT> 2 times that of the reference value);

- Patients with a history of allergy to heparin or protamine;

- Patients with history of heparin-induced thrombocytopenia;

- Tables infection (eg endocarditis, infection of immune human (HIV), hepatitis B and

C, septicemia and pneumonia);

- Reoperations;

- Use of antiplatelet (clopidogrel and ticlopidine) for less than 7 days;

- Use of acetylsalicylic acid is less than 5 days;

- Use of low molecular weight heparin for less than 24 hours; OR

- Use of non-fractioned heparin for less than 12 hours.

Locations and Contacts

LAL Clinica, Valinhos, SP 13270000, Brazil

Lal Clinica Pesquisa e Desenvolvimento Ltda, Valinhos, SP 13270-000, Brazil

Additional Information

Starting date: July 2009
Last updated: February 22, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017